nurandociguat (BAY 3283142) / Bayer - LARVOL DELTA

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer | Initiation date: Oct 2026 ➔ Jan 2027

Trial initiation date • Cardiovascular • Coronary Artery Disease

A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=1222 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

Effect of Nurandociguat on Albuminuria in Patients with CKD: A Phase 2, Randomized Dose-Finding Clinical Trial (ERA 2026) - P2 | "Further trials are needed to study the effect of nurandociguat on kidney and cardiovascular outcomes. Image"

Clinical • Late-breaking abstract • P2 data • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypotension • Metabolic Disorders • Nephrology • Renal Disease

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer | Trial completion date: Dec 2026 ➔ May 2027 | Trial primary completion date: Dec 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dabigatran in Healthy Adults (clinicaltrials.gov) - P1 | N=0 | Withdrawn | Sponsor: Bayer | N=40 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer | Initiation date: Apr 2026 ➔ Sep 2026

Trial initiation date • Cardiovascular • Coronary Artery Disease

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer

Trial initiation date • Cardiovascular • Coronary Artery Disease

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=1222 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed | N=700 ➔ 1222 | Trial completion date: Mar 2026 ➔ Nov 2025 | Trial primary completion date: Feb 2026 ➔ Oct 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dabigatran in Healthy Adults (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

22700: A study to learn about how a new nurandociguat tablet is absorbed and processed in the body compared to an old tablet and how food affects the way the new tablet is absorbed and processed in the body (clinicaltrialsregister.eu) - P1 | N=18 | Not yet recruiting | Sponsor: Bayer AG

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

22600: A study to learn more about how safe nurandociguat is and how it affects the way the body processes rosuvastatin and dabigatran in healthy adults (clinicaltrialsregister.eu) - P1 | N=40 | Not yet recruiting | Sponsor: Bayer AG

New P1 trial • Chronic Kidney Disease • Nephrology • Renal Disease

A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer

New P1 trial • Cardiovascular • Coronary Artery Disease

22598: A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension. (clinicaltrialsregister.eu) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer AG

New P1 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease. (clinicaltrialsregister.eu) - P1 | N=36 | Not yet recruiting | Sponsor: Bayer AG

New P1 trial • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Nephrology • Renal Disease

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure (clinicaltrials.gov) - P1 | N=75 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

NO- and Heme-Independent sGC Activators, Runcaciguat and Nurandociguat, as New Treatment Options for CKD: From Bench to Bedside (KIDNEY WEEK 2025) - P2 | "Conclusion These non-clinical and first clinical data strongly suggest that sGC activators could become an effective treatment option for CKD patients which can significantly reduce the residual risk of patients on top of optimized current therapies. Currently, nurandociguat is investigated clinically a phase 2 program in CKD patients (NCT06522997)."

Chronic Kidney Disease • Diabetic Nephropathy • Nephrology • Renal Disease

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: Bayer | Trial completion date: Jul 2025 ➔ Nov 2025 | Trial primary completion date: Jul 2025 ➔ Nov 2025

Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Pulmonary Arterial Hypertension • Renal Disease

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bayer | Recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Hepatology • Nephrology • Renal Disease

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Recruiting | Sponsor: Bayer | Trial completion date: Jun 2026 ➔ Mar 2026 | Trial primary completion date: May 2026 ➔ Feb 2026

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Trial completion • Chronic Kidney Disease • Diabetic Retinopathy • Nephrology • Renal Disease • Retinal Disorders

A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants (clinicaltrials.gov) - P1 | N=23 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Kidney Disease • Diabetic Retinopathy • Nephrology • Renal Disease • Retinal Disorders

ALPINE 1: A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease (clinicaltrials.gov) - P2 | N=700 | Recruiting | Sponsor: Bayer | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2026 ➔ Jun 2026

Enrollment open • Trial completion date • Chronic Kidney Disease • Congestive Heart Failure • Nephrology • Renal Disease